Cargando…

Dramatic response to immunotherapy in an epidermal growth factor receptor-mutant non-small cell lung cancer: A case report

BACKGROUND: The advent of immune checkpoint inhibitors (ICIs) has revolutionized the management of several types of solid cancers, including lung cancer, by boosting the body's natural tumor killing response. However, it is undeniable that only a small proportion of non-small cell lung cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ding, Cheng, Cheng, Song, Wen-Ping, Ni, Pei-Zan, Zhang, Wen-Zhou, Wu, Xuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717509/ https://www.ncbi.nlm.nih.gov/pubmed/35071573 http://dx.doi.org/10.12998/wjcc.v9.i36.11419

Ejemplares similares

Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2016)

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
por: Kelly, William J., et al.
Publicado: (2018)

Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Cost‐effectiveness analysis of first‐line treatments for advanced epidermal growth factor receptor‐mutant non‐small cell lung cancer patients
por: Li, Wen‐Qian, et al.
Publicado: (2021)

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
por: Cortot, Alexis B., et al.
Publicado: (2014)

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors
por: Bouchez, Clémentine, et al.
Publicado: (2020)

Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
por: Jabbari, Siavash, et al.
Publicado: (2011)

The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer
por: Ellis-Caleo, Tim, et al.
Publicado: (2021)

E-cadherin expression in the tumor microenvironment of advanced epidermal growth factor receptor-mutant lung adenocarcinoma and the association with prognosis
por: Chang, Yu-Ping, et al.
Publicado: (2023)

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
por: Liang, Hongge, et al.
Publicado: (2018)

Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis
por: Zeng, Xinmin, et al.
Publicado: (2020)

CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor
por: Liu, Bin, et al.
Publicado: (2019)

Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2016)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Epidermal growth factor receptors in non-small cell lung cancer.
por: Veale, D., et al.
Publicado: (1987)

Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study
por: Lei, Lei, et al.
Publicado: (2020)

Litchi seed extract inhibits epidermal growth factor receptor signaling and growth of Two Non-small cell lung carcinoma cells
por: Chung, Yuan-Chiang, et al.
Publicado: (2017)

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019)

Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
por: Wang, Shouzheng, et al.
Publicado: (2021)

Exploratory cohort study and meta-analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
por: Sun, Si, et al.
Publicado: (2017)

Inferior outcome of bone metastasis in non-small-cell-lung-cancer patients treated with epidermal growth factor receptor inhibitors
por: Chen, Yue-Yun, et al.
Publicado: (2021)

Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer
por: Valley, Christopher C., et al.
Publicado: (2015)

Bladder metastasis from epidermal growth factor receptor mutant lung cancer: A case report
por: Jin, Cai-Bao, et al.
Publicado: (2023)

Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
por: Gao, Yuan, et al.
Publicado: (2015)

Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
por: Lee, Dae Ho, et al.
Publicado: (2015)

Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity
por: Li, Ming, et al.
Publicado: (2022)

Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis
por: Zhang, Qiuyi, et al.
Publicado: (2016)

Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor
por: Minami, Seigo, et al.
Publicado: (2017)

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
por: Watanabe, Hiromi, et al.
Publicado: (2017)

Aluminosilicate Nanocomposite on Genosensor: A Prospective Voltammetry Platform for Epidermal Growth Factor Receptor Mutant Analysis in Non-small Cell Lung Cancer
por: Ramanathan, Santheraleka, et al.
Publicado: (2019)

Multidisciplinary and real life data: practical management of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)
por: D’Incecco, Armida, et al.
Publicado: (2022)

MIIP accelerates epidermal growth factor receptor protein turnover and attenuates proliferation in non-small cell lung cancer
por: Wen, Jing, et al.
Publicado: (2016)

Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations
por: Chang, Ming-Hung, et al.
Publicado: (2022)

Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation
por: Kuo, Chih-Hsi Scott, et al.
Publicado: (2022)

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
por: Feng, Yongdong, et al.
Publicado: (2021)

Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma
por: Zhu, You-Cai, et al.
Publicado: (2019)

Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors
por: Ma, Guangzhi, et al.
Publicado: (2017)

Estrogen Receptor β1 Expression Patterns Have Different Effects on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors’ Treatment Response in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma
por: Zhang, Lijuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ghbc8k2eiprmq57rl77573mg2p